1-3 of 3
Hong Zhu, PhD
Close
Sort by
Journal Articles

TG101209, a Selective JAK2 Kinase Inhibitor, Suppresses Endogenous and Cytokine-Supported Colony Formation from Hematopoietic Progenitors Carrying JAK2 V617F or MPL W515K/L Mutations.

Animesh Pardanani, MD, PhD, John Hood, PhD, Terra Lasho, Glenn Noronha, PhD, Christy Finke, Chi Ching Mak, PhD, Ruben Mesa, MD, Hong Zhu, PhD, Richard Soll, PhD, Ayalew Tefferi, MD
Journal: Blood
Blood (2006) 108 (11): 2680.
https://doi.org/10.1182/blood.V108.11.2680.2680
Published: 2006
Journal Articles

JAK2 Inhibitors for the Treatment of Myeloprolifertive Disorders.

John Hood, PhD, Jon Cao, PhD, Ehab Hanna, MS, Dan Lohse, PhD, Chi Ching Mak, PhD, Andrew McPherson, PhD, Glenn Noronha, PhD, Joel Renick, MS, Binqi Zheng, PhD, Hong Zhu, PhD, Richard Soll, PhD
Journal: Blood
Blood (2006) 108 (11): 3632.
https://doi.org/10.1182/blood.V108.11.3632.3632
Published: 2006
Journal Articles

In Vitro and In Vivo Inhibition of the T315I Mutant BCR/ABL Kinase.

Hong Zhu, PhD, Ehab Hanna, M.S., Dan Lohse, Ph.D., Silva Stoughton, B.S., Betty Tam, Ph.D., Kathy Barrett, M.S., Glenn Noronha, Ph.D., Elena Dneprovskaia, Ph.D., Jon Cao, Ph.D., Chun Chow, Ph.D., Linda Hwang, B.S., Chiching Mak, Ph.D., Andy McPherson, Ph.D., Moorthy Palanki, Ph.D., Ved P. Pathak, Ph.D., Joe Renick, M.S., Richard Soll, Ph.D., Binqi Zeng, Ph.D., John Hood, Ph.D.
Journal: Blood
Blood (2006) 108 (11): 2182.
https://doi.org/10.1182/blood.V108.11.2182.2182
Published: 2006